1-15 of 123
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
NephrologyOptimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
CME/CEPatient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
Jay B. Wish, MD
- advertisement
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents
Richard Lafayette, MD, FACP
Hong Zhang
Dana Rizk, MD
Suzuki Yusuke, MD, PhD
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Richard Lafayette, MD, FACP
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Hong Zhang
- advertisement
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®Emerging Therapies in IgAN: Who Could Benefit the Most?
Richard Lafayette, MD, FACP
Hong Zhang
